1. Home
  2. ONEG vs LEXX Comparison

ONEG vs LEXX Comparison

Compare ONEG & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneConstruction Group Limited Ordinary Shares

ONEG

OneConstruction Group Limited Ordinary Shares

HOLD

Current Price

$1.03

Market Cap

18.9M

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$4.75

Market Cap

16.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONEG
LEXX
Founded
2021
2004
Country
Hong Kong
Canada
Employees
26
7
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
16.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ONEG
LEXX
Price
$1.03
$4.75
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
49.0K
121.8K
Earning Date
01-14-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$0.35
52 Week High
$14.95
$1.55

Technical Indicators

Market Signals
Indicator
ONEG
LEXX
Relative Strength Index (RSI) 39.36 94.25
Support Level $0.96 $0.69
Resistance Level $1.98 N/A
Average True Range (ATR) 0.05 0.17
MACD 0.02 0.26
Stochastic Oscillator 8.55 80.27

Price Performance

Historical Comparison
ONEG
LEXX

About ONEG OneConstruction Group Limited Ordinary Shares

OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project includes performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: